BC1 (Bria-OTS) and BC1 (Bria-OTS) in combination with tislelizumab


Breast Cancer, Breast Tumor, Cancer of Breast, Malignant Tumor of Breast, Metastatic Breast Cancer, Other advanced solid tumors



A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

A Study of Bria-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

This is an open-label study to evaluate the safety and tumor response of BC1 cell line immunotherapy in patients with advanced late-stage metastatic breast cancer


  • BC1 (Bria-OTS)
  • Bria-OTS Regimen + CPI (tislelizumab)

Inclusion Criteria

  • Be ≥ 18 years of age.
  • Have signed informed consent.
  • Have histological confirmation of breast cancer with either locally recurrent unresectable and/or metastatic lesions, and have failed prior therapy.
  • Has expected survival of at least 4 months.
  • ECOG performance status of 0, 1 or 2
  • Patients must be stable with all known or expected toxicities from previous treatment


  • Sarcoma Oncology Center Recruiting
    Santa Monica, California, United States, 90403

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06471673